Antiphospholipid antibodies in lupus nephritis

PLoS ONE

Volumn 11, Issue 6, 2016, Pages

  Parodis, Ioannis ^a   Arnaud, Laurent ^a   Gerhardsson, Jakob ^a   Zickert, Agneta ^a   Sundelin, Birgitta ^a   Malmström, Vivianne ^a   Svenungsson, Elisabet ^a   Gunnarsson, Iva ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

BETA2 GLYCOPROTEIN 1 ANTIBODY; CARDIOLIPIN ANTIBODY; CREATININE; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN M ANTIBODY; LUPUS ANTICOAGULANT; PHOSPHOLIPID ANTIBODY; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M;

ADULT; AGED; ARTICLE; CHRONIC KIDNEY DISEASE; COHORT ANALYSIS; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; FEMALE; FOLLOW UP; GLOMERULUS FILTRATION RATE; HUMAN; IMMUNOGLOBULIN BLOOD LEVEL; LONGITUDINAL STUDY; LUPUS ERYTHEMATOSUS NEPHRITIS; MAJOR CLINICAL STUDY; MALE; MEMBRANOUS GLOMERULONEPHRITIS; OUTCOME ASSESSMENT; PROLIFERATIVE GLOMERULONEPHRITIS; PROSPECTIVE STUDY; SYSTEMIC LUPUS ERYTHEMATOSUS; VERY ELDERLY; ADOLESCENT; BIOPSY; BLOOD; HEALTH SURVEY; IMMUNOLOGY; LUPUS ERYTHEMATOSUS, SYSTEMIC; LUPUS NEPHRITIS; MIDDLE AGED; SWEDEN; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, ANTIPHOSPHOLIPID; BIOPSY; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; LUPUS ERYTHEMATOSUS, SYSTEMIC; LUPUS NEPHRITIS; MALE; MIDDLE AGED; PATIENT OUTCOME ASSESSMENT; PUBLIC HEALTH SURVEILLANCE; SWEDEN; YOUNG ADULT;

EID: 84976554672     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0158076     Document Type: Article

References (45)

1. Miyakis S, Lockshin MD, Atsumi T, Branch DW, Brey RL, Cervera R, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost. 2006; 4(2): 295-306. doi:10.1111/j.1538-7836.2006.01753.x PMID: 16420554.
2. Levine JS, Branch DW, Rauch J. The antiphospholipid syndrome. N Engl J Med. 2002; 346(10): 752- 63. doi:10.1056/NEJMra002974 PMID: 11882732.
3. Practice ACoO. ACOG practice bulletin. Diagnosis and management of preeclampsia and eclampsia. Number 33, January 2002. American College of Obstetricians and Gynecologists. Int J Gynaecol Obstet. 2002; 77(1): 67-75. PMID: 12094777.
4. Hughes GR, Harris NN, Gharavi AE. The anticardiolipin syndrome. J Rheumatol. 1986; 13(3): 486-9. PMID: 3735270.
5. Arnaud L, Mathian A, Devilliers H, Ruffatti A, Tektonidou M, Forastiero R, et al. Patient-level analysis of five international cohorts further confirms the efficacy of aspirin for the primary prevention of thrombosis in patients with antiphospholipid antibodies. Autoimmun Rev. 2015; 14(3): 192-200. doi:10.1016/j.autrev.2014.10.019 PMID: 25461472.
6. Cervera R, Piette JC, Font J, Khamashta MA, Shoenfeld Y, Camps MT, et al. Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1, 000 patients. Arthritis Rheum. 2002; 46(4): 1019-27. PMID: 11953980.
7. Nochy D, Daugas E, Droz D, Beaufils H, Grunfeld JP, Piette JC, et al. The intrarenal vascular lesions associated with primary antiphospholipid syndrome. J Am Soc Nephrol. 1999; 10(3): 507-18. PMID: 10073601.
8. Daugas E, Nochy D, Huong DL, Duhaut P, Beaufils H, Caudwell V, et al. Antiphospholipid syndrome nephropathy in systemic lupus erythematosus. J Am Soc Nephrol. 2002; 13(1): 42-52. PMID: 11752020.
9. Tektonidou MG, Sotsiou F, Nakopoulou L, Vlachoyiannopoulos PG, Moutsopoulos HM. Antiphospholipid syndrome nephropathy in patients with systemic lupus erythematosus and antiphospholipid antibodies: prevalence, clinical associations, and long- Term outcome. Arthritis Rheum. 2004; 50(8): 2569- 79. doi:10.1002/art.20433 PMID: 15334471.
10. Gerhardsson J, Sundelin B, Zickert A, Padyukov L, Svenungsson E, Gunnarsson I. Histological antiphospholipid- Associated nephropathy versus lupus nephritis in patients with systemic lupus erythematosus: An observational cross-sectional study with longitudinal follow-up. Arthritis Res Ther. 2015; 17: 109. doi:10.1186/s13075-015-0614-5 PMID: 25927214.
11. Song D, Wu LH, Wang FM, Yang XW, Zhu D, Chen M, et al. The spectrum of renal thrombotic microangiopathy in lupus nephritis. Arthritis Res Ther. 2013; 15(1): R12. doi:10.1186/ar4142 PMID: 23320601.
12. Zheng H, Chen Y, Ao W, Shen Y, Chen XW, Dai M, et al. Antiphospholipid antibody profiles in lupus nephritis with glomerular microthrombosis: A prospective study of 124 cases. Arthritis Res Ther. 2009; 11(3): R93doi:10.1186/ar2736 PMID: 19545416.
13. Moroni G, Ventura D, Riva P, Panzeri P, Quaglini S, Banfi G, et al. Antiphospholipid antibodies are associated with an increased risk for chronic renal insufficiency in patients with lupus nephritis. Am J Kidney Dis. 2004; 43(1): 28-36. PMID: 14712424.
14. Frampton G, Hicks J, Cameron JS. Significance of anti-phospholipid antibodies in patients with lupus nephritis. Kidney Int. 1991; 39(6): 1225-31. PMID: 1716712.
15. Mehrani T, Petri M. IgM anti-beta2 glycoprotein I is protective against lupus nephritis and renal damage in systemic lupus erythematosus. J Rheumatol. 2011; 38(3): 450-3. doi:10.3899/jrheum.100650 PMID: 21123325.
16. Bhandari S, Harnden P, Brownjohn AM, Turney JH. Association of anticardiolipin antibodies with intraglomerular thrombi and renal dysfunction in lupus nephritis. QJM. 1998; 91(6): 401-9. PMID: 9709458.
17. Cervera R, Khamashta MA, Font J, Sebastiani GD, Gil A, Lavilla P, et al. Systemic lupus erythematosus: clinical and immunologic patterns of disease expression in a cohort of 1, 000 patients. The European Working Party on Systemic Lupus Erythematosus. Medicine (Baltimore). 1993; 72(2): 113-24.
18. Farrugia E, Torres VE, Gastineau D, Michet CJ, Holley KE. Lupus anticoagulant in systemic lupus erythematosus: A clinical and renal pathological study. Am J Kidney Dis. 1992; 20(5): 463-71. PMID: 1442758.
19. Gulko PS, Reveille JD, Koopman WJ, Burgard SL, Bartolucci AA, Alarcon GS. Anticardiolipin antibodies in systemic lupus erythematosus: clinical correlates, HLA associations, and impact on survival. J Rheumatol. 1993; 20(10): 1684-93. PMID: 8295179.
20. Stratta P, Canavese C, Ferrero S, Grill A, Salomone M, Schinco PC, et al. Catastrophic antiphospholipid syndromes in systemic lupus erythematosus. Ren Fail. 1999; 21(1): 49-61. PMID: 10048117.
21. Parodis I, Zickert A, Sundelin B, Axelsson M, Gerhardsson J, Svenungsson E, et al. Evaluation of B lymphocyte stimulator and a proliferation inducing ligand as candidate biomarkers in lupus nephritis based on clinical and histopathological outcome following induction therapy. Lupus Sci Med. 2015; 2 (1): E000061doi:10.1136/lupus-2014-000061 PMID: 25632350.
22. Zickert A, Sundelin B, Svenungsson E, Gunnarsson I. Role of early repeated renal biopsies in lupus nephritis. Lupus Sci Med. 2014; 1(1): E000018. doi:10.1136/lupus-2014-000018 PMID: 25379188.
23. Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1982; 25(11): 1271-7. PMID: 7138600.
24. Petri M, Orbai AM, Alarcon GS, Gordon C, Merrill JT, Fortin PR, et al. Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum. 2012; 64(8): 2677-86. doi:10.1002/art.34473PMID: 22553077.
25. Weening JJ, D'Agati VD, Schwartz MM, Seshan SV, Alpers CE, Appel GB, et al. The classification of glomerulonephritis in systemic lupus erythematosus revisited. J Am Soc Nephrol. 2004; 15(2): 241-50. PMID: 14747370.
26. Austin HA III, Muenz LR, Joyce KM, Antonovych TA, Kullick ME, Klippel JH, et al. Prognostic factors in lupus nephritis. Contribution of renal histologic data. Am J Med. 1983; 75(3): 382-91. PMID: 6351607.
27. Gladman DD, Ibanez D, Urowitz MB. Systemic lupus erythematosus disease activity index 2000. J Rheumatol. 2002; 29(2): 288-91. PMID: 11838846.
28. Levey AS, Coresh J, Greene T, Stevens LA, Zhang YL, Hendriksen S, et al. Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann Intern Med. 2006; 145(4): 247-54. PMID: 16908915.
29. Renal Disease Subcommittee of the American College of Rheumatology Ad Hoc Committee on Systemic Lupus Erythematosus Response C. The American College of Rheumatology response criteria for proliferative and membranous renal disease in systemic lupus erythematosus clinical trials. Arthritis Rheum. 2006; 54(2): 421-32. doi:10.1002/art.21625 PMID: 16453282.
30. National Kidney F. K/DOQI clinical practice guidelines for chronic kidney disease: Evaluation, classification, and stratification. Am J Kidney Dis. 2002; 39(2 Suppl 1): S1-266. PMID: 11904577.
31. Levey AS. A decade after the KDOQI CKD guidelines. Am J Kidney Dis. 2012; 60(5): 683-5. doi:10.1053/j.ajkd.2012.08.019PMID: 23067628.
32. Levey AS, Eckardt KU, Tsukamoto Y, Levin A, Coresh J, Rossert J, et al. Definition and classification of chronic kidney disease: A position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int. 2005; 67(6): 2089-100. doi:10.1111/j.1523-1755.2005.00365.xPMID: 15882252.
33. Loizou S, Samarkos M, Norsworthy PJ, Cazabon JK, Walport MJ, Davies KA. Significance of anticardiolipin and anti-beta(2)-glycoprotein I antibodies in lupus nephritis. Rheumatology (Oxford). 2000; 39 (9): 962-8.
34. Fofi C, Cuadrado MJ, Godfrey T, Abbs I, Khamashta MA, Hughes GR. Lack of association between antiphospholipid antibody and WHO classification in lupus nephritis. Clin Exp Rheumatol. 2001; 19(1): 75-7. PMID: 11247329.
35. Berden AE, Nolan SL, Morris HL, Bertina RM, Erasmus DD, Hagen EC, et al. Anti-plasminogen antibodies compromise fibrinolysis and associate with renal histology in ANCA- Associated vasculitis. J Am Soc Nephrol. 2010; 21(12): 2169-79. doi:10.1681/ASN.2010030274 PMID: 20847144.
36. Bu C, Li Z, Zhang C, Gao L, Cai G. IgG antibodies to plasminogen and their relationship to IgG antibeta( 2)-glycoprotein 1 antibodies and thrombosis. Clin Rheumatol. 2008; 27(2): 171-8. doi:10.1007/s10067-007-0673-3 PMID: 17646899.
37. Conti F, Ceccarelli F, Perricone C, Leccese I, Massaro L, Pacucci VA, et al. The chronic damage in systemic lupus erythematosus is driven by flares, glucocorticoids and antiphospholipid antibodies: Results from a monocentric cohort. Lupus. 2016. doi:10.1177/0961203315627199.
38. Gladman D, Ginzler E, Goldsmith C, Fortin P, Liang M, Urowitz M, et al. The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index for systemic lupus erythematosus. Arthritis Rheum. 1996; 39(3): 363-9. PMID: 8607884.
39. Gerke V, Moss SE. Annexins: from structure to function. Physiol Rev. 2002; 82(2): 331-71. doi:10.1152/physrev.00030.2001 PMID: 11917092.
40. Allen KL, Fonseca FV, Betapudi V, Willard B, Zhang J, McCrae KR. A novel pathway for human endothelial cell activation by antiphospholipid/anti-beta2 glycoprotein I antibodies. Blood. 2012; 119(3): 884-93. doi:10.1182/blood-2011-03-344671 PMID: 22106343.
41. Cesarman-Maus G, Rios-Luna NP, Deora AB, Huang B, Villa R, Cravioto Mdel C, et al. Autoantibodies against the fibrinolytic receptor, annexin 2, in antiphospholipid syndrome. Blood. 2006; 107(11): 4375- 82. doi:10.1182/blood-2005-07-2636 PMID: 16493010.
42. Salle V, Maziere JC, Smail A, Cevallos R, Maziere C, Fuentes V, et al. Anti- Annexin II antibodies in systemic autoimmune diseases and antiphospholipid syndrome. J Clin Immunol. 2008; 28(4): 291-7. doi:10.1007/s10875-008-9188-1 PMID: 18322784.
43. Salle V, Maziere JC, Brule A, Schmidt J, Smail A, Duhaut P, et al. Antibodies against the N- Terminal domain of annexin A2 in antiphospholipid syndrome. Eur J Intern Med. 2012; 23(7): 665-8. doi:10.1016/j.ejim.2012.04.006 PMID: 22939813.
44. Yung S, Cheung KF, Zhang Q, Chan TM. Anti-dsDNA antibodies bind to mesangial annexin II in lupus nephritis. J Am Soc Nephrol. 2010; 21(11): 1912-27. doi:10.1681/ASN.2009080805 PMID: 20847146.
45. Salle V, Cordonnier C, Schmidt J, Maziere C, Smail A, Attencourt C, et al. Vascular expression of annexin A2 in lupus nephritis. J Clin Pathol. 2015. doi:10.1136/jclinpath-2015-203139.